Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANCALLO oral vancomycin prophylaxis for prevention of Clostridioides difficile infection after allogeneic hematopoietic stem cell transplantation
2024-513490-45-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2022
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing Oral vancomycin prophylaxis with Placebo oral prophylaxis (2 arms). Primary endpoint: Clostridioides difficile infection between inclusion and discharge or end of treatment. Started Oct 2022; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2024-513490-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513490-45-00.